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Abstract Mitochondrial dysfunction is involved in the
pathogenesis of neurodegenerative diseases, including
Parkinson’s disease (PD). Uncoupling proteins (UCPs)
delink ATP production from biofuel oxidation in mito-
chondria to reduce oxidative stress. UCP2 is expressed in
brain, and has neuroprotective effects under various toxic
insults. We observed induction of UCP2 expression by
leptin in neuronal cultures, and hypothesize that leptin may
preserve neuronal survival via UCP2. We showed that
leptin preserved cell survival in neuronal SH-SY5Y cells
against MPP
? toxicity (widely used in experimental Par-
kinsonian models) by maintaining ATP levels and mito-
chondrial membrane potential (MMP); these effects were
accompanied by increased UCP2 expression. Leptin had no
effect in modulating reactive oxygen species levels. Stable
knockdown of UCP2 expression reduced ATP levels, and
abolished leptin protection against MPP
?-induced mito-
chondrial depolarization, ATP deﬁciency, and cell death,
indicating that UCP2 is critical in mediating these neuro-
protective effects of leptin against MPP
? toxicity.
Interestingly, UCP2 knockdown increased UCP4 expres-
sion, but not of UCP5. Our ﬁndings show that leptin pre-
serves cell survival by maintaining MMP and ATP levels
mediated through UCP2 in MPP
?-induced toxicity.
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Introduction
Mitochondrial uncoupling proteins (UCPs) are solute car-
riers which can uncouple biofuel oxidation from ATP
synthesis by modulating proton gradient across the inner
mitochondrial membrane (Andrews et al. 2005; Krauss
et al. 2005). Partial uncoupling by UCPs may be a vital link
between ATP and reactive oxygen species (ROS) produc-
tion (Arsenijevic et al. 2000; Krauss et al. 2002), and UCPs
are critical in controlling oxidative stress produced by the
mitochondrial electron transport chain (Casteilla et al.
2001). Of ﬁve UCP homologues, UCP2 is ubiquitously
expressed (Fleury et al. 1997), whereas UCP4 and UCP5
are speciﬁcally expressed in brain (Mao et al. 1999; San-
chis et al. 1998). UCP2 has protective properties against
oxidative damage (Diano et al. 2003; Mattiasson et al.
2003), by modulating mitochondrial membrane potential
(MMP), mitochondrial proliferation, ATP and ROS levels.
UCP2 also has neuroprotective effects in different parkin-
sonian models (Conti et al. 2005; Andrews et al. 2006).
UCP2 knockout mice resulted in increased mitochondrial
ROS production (Arsenijevic et al. 2000).
Leptin is a circulating, 16 kDa hormone secreted by
adipocytes. It is a four-helical cytokine encoded by the
obese (ob) gene (Halaas et al. 1995). It regulates basal
metabolism and energy homeostasis via its peripheral
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tides in the ventro-medial hypothalamus (Friedman and
Halaas 1998; Spiegelman and Flier 2001). Leptin receptors
are widely expressed throughout brain, including substantia
nigra (Couce et al. 1997; Elmquist et al. 1998). Although
leptin receptors are localized in nigral dopaminergic neu-
rons, their role in these neurons remains unclear. Studies of
leptin in brain have mainly focused on its effects on
hypothalamus as a peripheral signal in regulating energy
balance and body weight (Friedman and Halaas 1998;
Spiegelman and Flier 2001). Efﬂux of leptin from brain
supports its direct action on the central nervous system
(Esler et al. 1998). Apart from being an energy-regulating
hormone, leptin has divergent effects on different brain
regions (Maratos-Flier 2008). Nevertheless, little is known
on whether leptin has any effect on mitochondria, the main
provider of cellular energy.
We reported previously that MPP
? toxicity (widely used
in experimental parkinsonian models) induced expression
of UCP2, 4, and 5 in neuronal cultures in a dose-dependent
manner, such that higher-toxicity levels induced greater
levels of their expression (Ho et al. 2005). Knockdown of
UCP5 expression increased MPP
?-induced neuronal cell
death (Ho et al. 2006). We have also reported that stable
overexpression of UCP4 in SH-SY5Y cells protected
against MPP
? and dopamine toxicity by reducing oxidative
stress, preserving MMP and ATP levels (Chu et al. 2009).
The protective effects of leptin have been reported in dif-
ferent tissues, including neurons, under a variety of insults,
including MPP
? (Russo et al. 2004; Guo et al. 2008; Weng
et al. 2007; Zhang et al. 2007). We noted that leptin can
also modulate UCP expression in nonneuronal tissues
(Ceddia et al. 2000; Ricquier and Bouillaud 2000). It is not
known whether leptin can affect mitochondrial function,
and if so, whether this effect is mediated via UCP2
expression. We observed that leptin-induced UCP2
expression in neuronal cultures, and hypothesize that lep-
tin, via UCP2, may preserve neurons in MPP
? toxicity. In
this study, we explored the effects of leptin in MPP
?-
induced mitochondrial dysfunction and oxidative stress in
SH-SY5Y cells, with and without knocking down UCP2
expression.
Materials and Methods
Materials
Human neuroblastoma SH-SY5Y (CRL-2266) cells were
obtained from American Type Culture Collection (ATCC);
Dulbecco’s modiﬁed Eagle’s medium/F12 (DMEM/F12),
fetal bovine serum (FBS) from GibcoBRL (Gaithersburg,
MD, USA); human recombinant leptin and MPP
? iodide
from Sigma–Aldrich; BLOCK-iT Pol II miR RNAi
expression vector kits from Invitrogen; ATP determination
kit from Perkin-Elmer (MA, USA); 5,50,6,60-tetrachloro-
1,10,3,30-tetraethylbenzimidazolyl carbocyanine iodide
(JC-1), tetramethylrhodamine methyl ester (TMRM), and
dihydroethidium (DHE) from Molecular Probes (Eugene,
OR); Taqman
TM EZ RT-PCR reagent kit, probes, and
StepOne
TM Real-time PCR system from Applied Biosys-
tems (ABI); cell lysis buffer for protein extraction was
from Cell Signaling Technology (MA, USA); protease
inhibitor cocktail was from Roche (Germany); polyclonal
antibodies against human UCP2 from Alpha Diagnostic
International, Inc. (San Antonio, TX); polyclonal anti-
COX-IV antibody, monoclonal anti-actin from Santa Cruz
Biotechnology (Santa Cruz, CA); horseradish peroxidase-
conjugated secondary antibodies from DAKO (Carpinteria,
CA); ECL western blotting detection system from Amer-
sham Biosciences (Buckinghamshire, UK); GeneTools
TM
Analysis Software version 3.02 from Syngene (UK); and
CellQuest
TM ﬂow cytometry software from BD Biosci-
ences (CA, USA).
Cell Culture and Treatment
Human SH-SY5Y cells were cultured in DMEM/F12
supplemented with 10% FBS, 2 mM L-glutamine, and
100 lg/ml penicillin–streptomycin at 37C in humidiﬁed
5% CO2 atmosphere. Cells seeded in 24-well plates at 70%
conﬂuence. Cells were treated with 0.5 mM MPP
? (freshly
prepared in PBS) with or without leptin (100 nM) for 24 h
in DMEM/F12 medium supplemented with 10% charcoal-
stripped bovine serum. Cytotoxicity levels after treatment
were determined by radioactive [
3H]thymidine uptake
assay and lactate dehydrogenase (LDH) release assay.
Total RNA was extracted by Trizol
TM for real-time quan-
titative RT-PCR. In parallel, live cells after treatment were
collected for measurements of MMP and oxidative stress
(ROS) by ﬂow cytometry.
Stable Knockdown of UCP2 Expression
Four pre-designed artiﬁcial microRNA (miRNA) oligo-
duplexes encoding sequences against human UCP2 were
cloned separately into a mammalian miRNA expression
vector (pcDNA6.2-GW/EmGFP-miR; Invitrogen). Sequen-
ces of the cloning oligos are summarized in Table 1. These
plasmids were co-transfected into SH-SY5Y cells using
Lipofectamine2000
TM at a ratio of 2:1 to the amount of
plasmid DNA. Twenty-four hours after transfection, cells
were selected using blasticidin (4 lg/ml) to obtain single
resistant colonies which stably expressed miRNA to trigger
genesilencing.Thetransfectionefﬁciencyoftargetplasmids
into SH-SY5Y cells was monitored by expression of GFP
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each clone was conﬁrmed by western blotting.
Cell Proliferation and Viability
Cell viability in nondifferentiated cells was measured as
the rate of cell proliferation by [
3H]thymidine uptake assay
as previously described (Chu et al. 2009). Cells were see-
ded at a density of 1 9 10
5 cells/ml in 96-well plates and
treated with 0.5 mM MPP
? with or without leptin
(100 nM) for 24 h. Six hours before the end of the treat-
ment, cells were incubated with
3H-thymidine (1 lCi/ml).
Cells were lysed and total DNA was harvested using an
automated harvester (Filtermate Harvester Packard Bio-
science Co.). The rate of cell proliferation was expressed as
the percentage changes in the radioactivity of the samples
counted in a liquid scintillation counter (Topcount, NXT
Packard Bioscience Co.) compared with untreated controls.
Cell viability in fully differentiated cells was also esti-
mated using LDH release assay as described (Ho et al.
2005). Cells were differentiated by trans-retinoic acid
(10 lM) for 7 days, and then treated with 0.5 mM MPP
?
with or without leptin (100 nM) for 48 h. The level of
neuronal cell death was estimated by measuring the activity
of released LDH in culture medium from each treatment
group. Cytotoxicity was deﬁned as the percentage increase
in LDH release compared with untreated controls after
normalization by total protein extractable from the culture.
Detection of Intracellular ROS
Intracellular oxidant levels in cells were measured based on
oxidation of superoxide-sensitive DHE as previously
described (Chu et al. 2009). Brieﬂy, after treatment, the
cells were incubated in DHE (10 lM) for 30 min at 37C
in the dark. The cells were washed with PBS and collected
by trypsinization. Red ﬂuorescence from the oxidation of
DHE was monitored using a 585-nm ﬁlter (FL2-channel).
The oxidant level was deﬁned as the relative ﬂuorescent
intensity compared with that of vector controls.
Measurement of MMP
Changes in MMP in normal SH-SY5Y cells were measured
by ﬂow cytometry based on MMP-sensitive ratiometric
ﬂuorescent dye 5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-
benzimidazolyl carbocyanine iodide (JC-1) staining as
previously described (Chu et al. 2009). Brieﬂy, cells
(1 9 10
6) were trypsinized in 1 ml of medium and incu-
bated with 10 lg/ml of JC-1 for 20 min at 37C in the
dark. After incubation, the cells were washed and resus-
pended in PBS in a total volume of 0.5 ml. The intensity of
both red and green colors was determined by ﬂow
cytometry. A minimum of 10,000 events per sample were
acquired per analysis. Relative MMP was deﬁned as the
ratio between green and red signals.
Since the UCP2 knockdown cells expressed green
ﬂuorescent protein (EGFP), which may interfere the ra-
tiometric measurement of MMP by JC-1, changes in MMP
between UCP2 knockdown and vector control cells were
estimated by ﬂow cytometry after staining with another
MMP-sensitive ﬂuorescent dye, TMRM (Distelmaier et al.
2008; Scaduto and Grotyohann 1999). Brieﬂy, cells
(1 9 10
6) were trypsinized in 1 ml of medium and incu-
bated with 200 nM of TMRM for 15 min at 37C in the
dark. After incubation, the cells were washed and resus-
pended in medium in a total volume of 1 ml. The relative
MMP was estimated by the level of red ﬂuorescence (FL-2)
as measured by ﬂow cytometry.
Measurement of Intracellular ATP
Intracellular ATP levels were assayed by utilizing lucif-
erin-luciferase bioluminescene assay as previously descri-
bed (Chu et al. 2009). Brieﬂy, cells were washed with PBS
and harvested 24 h after treatments. Total ATP was
extracted in lysis buffer containing: 100 mM potassium
phosphate buffer (pH 7.8), 2 mM EDTA, 1 mM DTT, and
1% Triton X-100. Samples were immediately frozen after
extraction at -80C until use. ATP concentrations were
determined using a calibration curve of serial ATP
Table 1 DNA sequences of UCP2 miRNA oligos
Oligo name Sequence
Hmi418044-UCP2-sense 50-TGCTGTTTAGCAGTATCCAGAGGAAAGTTTTGGCCACTGACTGACTTTCCTCTATACTGCTAAA-30
Hmi418044-UCP2-antisense 50-CCTGTTTAGCAGTATAGAGGAAAGTCAGTCAGTGGCCAAAACTTTCCTCTGGATACTGCTAAAC-30
Hmi418045-UCP2-sense 50-TGCTGTTTGACAGAATCATACAGGCCGTTTTGGCCACTGACTGACGGCCTGTAATTCTGTCAAA-30
Hmi418045-UCP2-antisense 50-CCTGTTTGACAGAATTACAGGCCGTCAGTCAGTGGCCAAAACGGCCTGTATGATTCTGTCAAAC-30
Hmi418046-UCP2-sense 50-TGCTGAATGCTGGCATGCTCAGAGCCGTTTTGGCCACTGACTGACGGCTCTGAATGCCAGCATT-30
Hmi418046-UCP2-antisense 50-CCTGAATGCTGGCATTCAGAGCCGTCAGTCAGTGGCCAAAACGGCTCTGAGCATGCCAGCATTC-30
Hmi418047-UCP2-sense 50-TGCTGATTACGAGCAACATTGGGAGAGTTTTGGCCACTGACTGACTCTCCCAATTGCTCGTAAT-30
Hmi418047-UCP2-antisense 50-CCTGATTACGAGCAATTGGGAGAGTCAGTCAGTGGCCAAAACTCTCCCAATGTTGCTCGTAATC-30
334 Neurotox Res (2010) 17:332–343
123dilutions provided in the kit and compared with normal
vector controls. Aliquots from each sample extract were
used to measure total protein for normalization.
Real-Time Quantitative RT-PCR of Steady-State
mRNA Levels
UCPs mRNA expression was determined by quantitative
RT-PCR. Total RNA was isolated and digested with DNase
I as previously described (Ho et al. 2005). The OD260/280
ratio of extracted RNA was kept above 1.95 to ensure
purity and integrity. The thermal cycling conditions were
as follows: 2 min at 50C; 30 min at 60C and 5 min at
95C followed by 40 cycles of 95C for 20 s and 62C for
1 min in Taqman
TM EZ RT-PCR reaction mixtures. Each
RNA sample was run in triplicate and repeated in at least
three independent treatments. 18S-rRNA expression was
used to normalize for mRNA loading. All reactions were
performed using StepOne
TM Real-time PCR System (ABI).
Western Blotting
Total cell lysate was extracted in 19 cell lysis buffer (Cell
Signaling Technology, Inc.), supplemented with 1 mM
phenylmethylsulfonyl ﬂuoride. Equal amounts of protein
(30 lg) were electrophoresed on 15% SDS-PAGE and
transferred onto PVDF-membrane. Resulting blots were
blocked with 5% nonfat skimmed milk and probed with the
following: anti-UCP2 (1:1000), anti-COXIV (1:10000), or
anti-actin (1:500). Blots were incubated with horseradish
peroxidase-conjugated secondary antibodies (1:5000) fol-
lowed by ECL substrate detection. Immunoblots were
quantiﬁed by computerized scanning densitometry.
Statistics
Data are expressed as mean ± standard error mean (SEM)
from at least four independent experiments. GraphPad
PRISM software (Graph Pad Inc., San Diego, CA) was
used to calculate statistical signiﬁcance P values among
groups using one-way ANOVA followed by the post hoc
Tukey’s multiple comparison tests. Differences were con-
sidered signiﬁcant at P\0.05.
Results
Leptin Preserved Cell Survival Against MPP
?-Induced
Toxicity
To determine whether leptin could protect against MPP
?
toxicity, both differentiated and nondifferentiated
SH-SY5Y cells were exposed to MPP
?, with or without
leptin treatment in charcoal-stripped medium. At 24 h,
human recombinant leptin (100 nM) alone increased cell
proliferation in nondifferentiated cells (by 18%) compared
with untreated controls (P\0.01) (Fig. 1a). At 24 h,
MPP
? (0.5 mM) signiﬁcantly decreased cell proliferation
by 23% compared with untreated controls (P\0.01).
Combined treatment with leptin and MPP
? maintained cell
proliferation at a rate similar to that of untreated cells and
at a signiﬁcantly greater rate (by 20%) compared with cells
exposed to MPP
? only (P\0.01) (Fig. 1a).
Leptin treatment alone did not affect cell viability as
measured by LDH release in differentiated cells (Fig. 1b).
Exposure to MPP
? (0.5 mM) for 48 h signiﬁcantly
increased cell death (by 17%) compared with untreated
controls (P\0.01). Leptin with MPP
? signiﬁcantly pre-
served cell survival (by 9%) compared with MPP
? only
(P\0.05; Fig. 1b). These ﬁndings indicate signiﬁcant
Fig. 1 Leptin protects against MPP
?-induced cell death in SH-SY5Y
cells. a Cell proliferation was measured by [
3H]thymidine uptake
assay in nondifferentiated cells after MPP
? (0.5 mM) exposure for
24 h. b The level of cell death was measured by LDH release assay in
differentiated nonreplicating cells after MPP
? (0.5 mM) exposure for
48 h. Results are mean ± SEM of four separate experiments (N = 4).
Statistical signiﬁcance at * P\0.05; ** P\0.01, compared to
untreated vector controls
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? toxicity in
SH-SY5Y cells.
Leptin Preserved MMP but had no Effect
on Oxidative Stress Induced by MPP
?
Relative MMP was determined by JC-1 staining following
exposure to MPP
?, with and without leptin. Incubation
with leptin alone did not change MMP levels compared
with untreated controls (Fig. 2a). At 24 h, MPP
? (0.5 mM)
caused signiﬁcant mitochondrial membrane depolarization
(from 0.21 ± 0.03 to 0.47 ± 0.08; P\0.01). Leptin sig-
niﬁcantly attenuated this MPP
?-induced mitochondrial
membrane depolarization (by 32%; P\0.01; Fig. 2a).
Leptin treatment alone did not increase the ROS level
compared with untreated cells. MPP
? (0.5 mM) signiﬁ-
cantly increased ROS levels (by 3-fold) compared with
untreated controls at 24 h (P\0.01), but leptin did not
attenuate this increase in ROS levels induced by MPP
?
(Fig. 2b).
Leptin Preserved Cellular ATP Levels in MPP
?-
Induced Toxicity
Incubation with leptin alone for 24 h did not change the
basal ATP level compared with untreated controls. MPP
?
(0.5 mM) signiﬁcantly decreased the intracellular ATP
level (by 23%) compared with untreated controls (from
0.477 ± 0.03 to 0.369 ± 0.01 nmol/mg; P\0.05). Leptin
treatment signiﬁcantly preserved ATP levels under MPP
?
toxicity, similar to controls without MPP
? (P\0.01;
Fig. 2c).
Both Leptin and MPP
? Increased UCP2 and UCP4
Expression, but not UCP5 in Control Cells
The role of UCP2 in mediating the protective effects of
leptin was explored by measuring UCP2 mRNA and pro-
tein expression after treatment with leptin and MPP
?.I n
control cells, incubation with leptin for 24 h increased
UCP2 mRNA (by 32%; P\0.01) and protein levels (by
184%; P\0.01). MPP
? (0.5 mM) at 24 h also signiﬁ-
cantly increased UCP2 mRNA (by 37%; P\0.01) and
protein expression (by 193%; P\0.01) compared with
untreated controls. Combined treatment with both leptin
and MPP
? did not further increase UCP2 expression,
compared with cells treated with either leptin or MPP
?
alone (Fig. 3a, b).
We have previously reported neuroprotective effects of
overexpressing UCP4 and potential compensatory effects
between UCP2 and UCP4 expression in MPP
? toxicity
(Chu et al. 2009). Hence, we explored whether leptin could
also affect UCP4 expression in response to changes in
UCP2 expression. Here, we showed that leptin alone
induced the steady-state UCP4 mRNA level (by 26%;
P\0.01) compared with untreated controls. MPP
? sig-
niﬁcantly increased UCP4 mRNA level (by 19%;
P\0.01; Fig. 5a) compared with untreated controls at
24 h, consistent with our previous report (Ho et al. 2005).
Combined treatment with leptin and MPP
? did not alter
UCP4 expression further compared with either leptin or
MPP
? alone (Fig. 5a).
For UCP5, leptin alone had no signiﬁcant effect on
UCP5 mRNA levels in control cells, whereas exposure of
these cells to MPP
? toxicity caused a signiﬁcant increase
(by 13%; P\0.05; Fig. 5b). Combine treatment with
Fig. 2 Leptin prevented MPP
?-induced depolarization of MMP, pre-
served ATP levels, but no effect on oxidative stress in SH-SY5Y cells.
SH-SY5Ycellswereexposedto0.5 mMMPP
?for24 hwithandwithout
leptin. a Cells after treatment were stained with JC-1, and the relative
MMPwasexpressedastheratioofgreentoredﬂuorescencemeasuredby
ﬂow cytometry. b Cells after treatment were stained with DHE, and the
level of oxidative stress was expressed as the level of red ﬂuorescence
measured by ﬂow cytometry. c Total intracellular ATP levels were
measured by utilizing luciferin-luciferase bioluminescene assay, 24 h
aftertreatments.Resultsareexpressedasmean ± SEMofthreeseparate
experiments (N = 3). Statistical signiﬁcance at the level of * P\0.05;
** P\0.01, compared to untreated controls. Statistical signiﬁcance at
the level of ** P\0.01, between two treatment groups indicated
336 Neurotox Res (2010) 17:332–343
123leptin and MPP
? increased UCP5 mRNA levels to a sim-
ilar extent to that caused by MPP
? alone (Fig. 5b).
Stable Knockdown of UCP2 Expression Increased
MMP
Our above results in control cells showed that either leptin
or MPP
? alone, and combined treatment increased UCP2
mRNA and protein expression (Fig. 3). We also showed
that leptin signiﬁcantly reduced MPP
? toxicity (Fig. 1),
indicating that UCP2 may be involved in the protective
properties of leptin. Hence, we developed a cell model in
which UCP2 expression was stably knocked down by
transfection of a plasmid overexpressing miRNA against
human UCP2. In this cell model, UCP2 knockdown was
demonstrated by a 48% reduction in UCP2 protein
expression (Fig. 4a). The MMP of these UCP2-knockdown
cells relative to the empty-vector controls was measured by
Fig. 3 Leptin and MPP
? induced UCP2 mRNA and protein expres-
sion in SH-SY5Y cells. a The steady-state UCP2 mRNA expression
was measured and normalized by rRNA-18S level by quantitative
RT-PCR. Leptin treatment and MPP
? exposure for 24 h increased
UCP2 mRNA expression compared to the untreated controls. b Under
the same treatment, leptin and MPP
? increased UCP2 protein
expression as shown by western blot. Combination of leptin and
MPP
? did not further increased UCP2 mRNA and protein expression.
Results are mean ± SEM of four separate experiments (N = 4).
Statistical signiﬁcance at the level of ** P\0.01, as compared to
untreated controls
Fig. 4 StableknockdownofUCP2inSH-SY5YcellsdecreasedUCP2
protein expression (a), and increased MMP under normal untreated
condition (b), as compared to vector controls. The relative MMP
between UCP2 knockdown and vector control cells was expressed as
levels of red ﬂuorescence measured by ﬂow cytometry after staining
with 200 nM TMRM for 15 min. Results are mean ± SEM of three
separate experiments (N = 3). Statistical signiﬁcance at the level of
** P\0.01, as compared to untreated vector controls
Fig. 5 Steady-state mRNA expression of UCP4 (a) and UCP5 (b)i n
both UCP2 knockdown and vector control cells. Leptin treatment and
MPP
? exposure increased UCP4 mRNA expression. Stable knock-
down of UCP2 also increased UCP4 mRNA expression, but not
UCP5. UCP5 mRNA expression was only induced by MPP
?
exposure. Results are mean ± SEM of three separate experiments
(N = 3). Statistical signiﬁcance at * P\0.05; ** P\0.01, as
compared to untreated vector controls.
# P\0.05;
## P\0.01, as
compared to untreated UCP2 knockdown cells
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ditions, UCP2-knockdown cells showed a signiﬁcantly
higher MMP compared with vector controls as shown by a
5.8-foldstrongerTMRMstaininginUCP2-knockdowncells
(P\0.01) (Fig. 4b). These results demonstrated classical
uncoupling properties of UCP2 (Fleury et al. 1997).
Effects of Knockdown of UCP2 Expression, Leptin,
and MPP
? on UCP4 and UCP5 Expression
To explore whether UCP2-knockdown affected other
neuronal UCPs (namely UCP4 and 5), their mRNA levels
were determined by quantitative RT-PCR after UCP2-
knockdown. Treatment with either leptin or MPP
? signif-
icantly increased UCP4 mRNA levels in UCP2-knockdown
cells similar to those observed in the vector control cells as
described above. Interestingly, the magnitude of differ-
ences in UCP4 mRNA levels between the various treat-
ments and their respective controls appeared to be greater
in UCP2-knockdown cells compared with changes seen in
vector control cells. In untreated conditions, UCP4 mRNA
levels were 35% higher in UCP2-knockdown cells, com-
pared with vector controls (P\0.01) (Fig. 5a). In UCP2-
knockdown cells, leptin increased UCP4 mRNA expression
by 31% (P\0.05), and MPP
? toxicity by 47% (P\0.01),
compared with untreated controls. Only MPP
? toxicity
alone caused a small but signiﬁcant increase in UCP5
mRNA (Fig. 5b).
Knockdown of UCP2 Expression Reduced ATP Levels
and Negated the Protective Effects of Leptin Against
ATP Deﬁciency
Knockdown of UCP2 expression signiﬁcantly decreased
total ATP levels by 26%, compared with vector controls
(P\0.01; Fig. 6). Furthermore, unlike vector control cells
(Fig. 2c), leptin failed to preserve cellular ATP levels in
UCP2-knockdown cells exposed to MPP
? toxicity. Sur-
prisingly, ATP levels in leptin-treated UCP2-knockdown
cells were even lower than untreated vector control cells
exposed to MPP
? (P\0.05; Fig. 6).
Knockdown of UCP2 Expression Abolished Leptin
Protection Against Cell Death and Mitochondrial
Depolarization Induced by MPP
?
Our results above showed that leptin can protect against
mitochondrial depolarization induced by MPP
? in normal
SH-SY5Y cells. To further explore the role of UCP2 in the
protective properties of leptin, both UCP2-knockdown and
vector control SH-SY5Y cells were challenged with MPP
?
(0.5 mM), with or without leptin (100 nM) for 24 h. Cells
after treatment were stained with TMRM to measure the
relative MMP. Similar to our results obtained above using
JC-1 staining, MPP
? (0.5 mM) caused signiﬁcant mito-
chondrial membrane depolarization (from 2.15 ± 0.06 to
0.94 ± 0.09; P\0.01). Leptin signiﬁcantly attenuated this
MPP
?-induced mitochondrial membrane depolarization
(by 41%; P\0.05; Fig. 7a). However, this protective
effect of leptin against mitochondrial depolarization was
not observed in UCP2-knockdown cells (Fig. 7b), indi-
cating that UCP2 is critical in mediating protection of
leptin against mitochondrial depolarization induced by
MPP
? toxicity.
Fig. 6 Knockdown of UCP2 expression decreased intracellular ATP
levels compared to the vector controls. UCP2 knockdown also
abolished leptin protection against MPP
?-induced ATP deﬁciency
and further decreased the ATP level as compared to the group
exposure to MPP
? only. Combination of leptin and MPP
? in UCP2
knockdown cells further decreased ATP level as compared to the
group exposure to MPP
? only. Results are mean ± SEM of four
separate experiments (N = 4). Statistical signiﬁcance at * P\0.05;
** P\0.01, as compared to untreated controls
Fig. 7 Leptin attenuated MPP
?-induced depolarization of MMP in
normal SH-SY5Y cells (a), but not in UCP2 knockdown cells (b).
SH-SY5Y cells were exposed to 0.5 mM MPP
? for 24 h, with and
without leptin. Cells after treatment were stained with 200 nM
TMRM for 15 min., and the relative MMP was expressed as levels of
red ﬂuorescence measured by ﬂow cytometry. Results are expressed
as mean ± SEM of three separate experiments (N = 3). Statistical
signiﬁcance at the level of * P\0.05; ** P\0.01, compared to the
respective untreated controls. Statistical signiﬁcance at the level of
# P\0.01, between two treatment groups indicated
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123Moreover, stable knockdown of UCP2 expression did
not affect the rate of cell proliferation in nondifferentiated
cells (Fig. 8a), and did not cause cytotoxicity in differen-
tiated cells (Fig. 8b) compared with empty-vector controls
under normal conditions. Similar to vector control cells
(Fig. 1a), leptin treatment alone signiﬁcantly increased
proliferation of UCP2-knockdown cells (by 20%;
P\0.01) compared with untreated controls (Fig. 8a).
Following combined treatment with leptin and MPP
?,
unlike the results in vector control cells, the protective
effects of leptin against cell death were not observed in
either nondifferentiated or differentiated UCP2-knockdown
cells (Fig. 8a, b).
Leptin Protection Against MPP
? Toxicity
was not Associated with Mitochondrial Proliferation
Because leptin preserved ATP levels in vector control but
not in UCP2-knockdown cells exposed to MPP
?,w e
determined whether the protective effects associated with
leptin were due to mitochondrial proliferation. We com-
pared the expression of a mitochondrial marker, COX-IV,
with that of a nuclear encoded housekeeping gene product,
actin, by western blotting. The relative amount of mito-
chondria was expressed as the ratio of COX-IV to actin.
The relative amounts of mitochondria between vector
control and UCP2-knockdown cells were similar under
normal culture conditions and in leptin-treated cells
exposed to MPP
? (Fig. 9), indicating that UCP2-knock-
down did not affect mitochondrial proliferation rates, and
that the preservation of ATP levels by leptin was not due to
mitochondrial proliferation.
Discussion
Mitochondrial dysfunction, as a consequence of mito-
chondrial Complex I inhibition, causes oxidative stress and
ATP deﬁciency in neurons (Beal 2003; Dawson and
Dawson 2003; Dauer and Przedborski. 2003). Despite
distinctive expression proﬁles among the neuronal UCPs
(Andrews et al. 2005; Fleury et al. 1997; Mao et al. 1999;
Sanchis et al. 1998), their physiological functions are
unclear. We and others have shown that increased
expression of these UCPs reduced the level of cell death
under different insults, including MPP
?, MPTP, and
6-hydroxydopamine toxicity (Chu et al. 2009; Andrews
et al. 2006; Chan et al. 2006; Conti et al. 2005). Because
human SH-SY5Y neuroblastoma cells express the leptin
receptor, they represent an appropriate homogeneous
culture model to study the effects of leptin on neuronal
cells (Lu et al. 2006; Benomar et al. 2005).
To demonstrate the neuroprotective effects of leptin on
mitochondrial dysfunction, MPP
? was used to induce ATP
deﬁciency and oxidative stress. MPP
? speciﬁcally blocks
mitochondrial Complex I activity, which impairs oxidative
Fig. 8 a Effects of UCP2 knockdown on cell proliferation in
nondifferentiated SY-SY5Y cells. Knockdown of UCP2 expression
did not affect the rate of cell proliferation under normal culture
condition, but abolished leptin protection against MPP
? toxicity. b
Effects of UCP2 knockdown on leptin protection against MPP
?
toxicity in differentiated SY-SY5Y cells. Results are mean ± SEM of
four separate experiments (N = 4). Statistical signiﬁcance at
** P\0.01, as compared to untreated controls
Fig. 9 UCP2 knockdown did not affect mitochondrial proliferation
as estimated by the protein expression of COX-IV/actin ratio. Results
are mean ± SEM of three separate experiments (N =3 )
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123phosphorylation and subsequently suppresses ATP pro-
duction and generates ROS. We previously showed that
MPP
? toxicity signiﬁcantly induced expression of UCP2, 4
and 5 in neuronal culture (Ho et al. 2005), which we
interpreted as defensive responses to counteract the effects
of mitochondrial dysfunction induced by this toxin. In this
study, we found that treatment with leptin protected neu-
ronal cells against MPP
?-induced toxicity. This was
accompanied by stabilization of MMP at levels similar to
untreated cells, and by signiﬁcant preservation of total
intracellular ATP concentrations. We not only showed the
ability of leptin to modulate MMP and ATP production in
our neuronal culture, our ﬁndings also demonstrated an
inductive effect of leptin in increasing expression of UCP2
and UCP4, but not UCP5. Nevertheless, leptin did not have
any direct effects in suppressing MPP
?-induced ROS
production in these cells. These observations suggest the
existence of mitochondrial pathways, potentially activated
by leptin, to promote cell survival via its effects on neu-
ronal UCPs.
UCP2 expression was induced by MPP
?, consistent with
our previous report (Ho et al. 2005). UCP2 expression was
also signiﬁcantly induced after incubation with leptin
alone, to a level similar to the cells exposed to MPP
?.
Nevertheless, incubation of leptin alone did not cause
increased cytotoxicity. Cell death induced by MPP
? was
remarkably reduced by co-treatment with leptin. Interest-
ingly, combined leptin and MPP
? treatment did not further
increase the expression of UCP2, when compared with
levels in cells exposed to either leptin or MPP
?. We also
observed protective effects of leptin, in that levels of cell
survival, MMP, and intracellular ATP were preserved.
These effects were abolished after UCP2 knockdown.
Thus, the protective effects of leptin were dependent on the
presence of UCP2. Nevertheless, whether UCP2 directly
interacts with proteins in the mitochondrial respiratory
chain in response to leptin signaling is still unclear.
The increase in UCP2 expression after MPP
? toxicity
was likely due to increased ROS generation mediated by
mitochondrial Complex I inhibition by this toxin, as pre-
viously proposed (Echtay et al. 2002; Brand et al. 2004;
Krauss et al. 2003). Moreover, induction of UCP2
expression was also observed after leptin exposure under
normal culture conditions (Fig. 3). In our study, the
increase in UCP2 expression was not due to an increase in
ROS, because leptin treatment did not signiﬁcantly
increase the ROS level. Leptin can modulate the phos-
phatidylinositol-3-kinase-phosphodiesterase 3B-cAMP
pathway (Sahu 2004). Multiple cAMP-response element
binding protein (CREB) response elements have been
reported in human UCP2 promoter region (Tu et al. 1999).
It is possible that leptin-induced UCP2 expression occurs
via the cAMP signaling pathway. Furthermore, because we
did not observe signiﬁcant additive effects on the level of
UCP2 expression after combined treatment with leptin and
MPP
?, it is reasonable to propose that the protective effects
of leptin were not dependent on a still further increase in
UCP2 expression.
There is considerable evidence to indicate that UCP2 is
neuroprotective in various experimental models. UCP2 has
been shown to play an important role in neurons to
diminish free radicals (Andrews et al. 2006; Conti et al.
2005), to decrease calcium inﬂux into mitochondria
(Mattiasson et al. 2003), and to elevate cellular ATP levels
(Diano et al. 2003). Exactly how UCP2 and leptin interact
to achieve the protective effect reported here is still poorly
understood. Functional linkages have been observed
between leptin and UCP2 in peripheral tissues. For exam-
ple, leptin diminished UCP2 abundance in pancreas but not
brain during neonatal development (Gnanalingham et al.
2005), whereas signiﬁcant upregulation of UCP2 by leptin
was observed in preadipocytes (Luo et al. 2008). UCP2 was
shown to promote fatty acid oxidation and limit glycolysis-
derived pyruvate catabolism (Pecqueur et al., 2008; Tajima
et al. 2005) and to regulate the choice of mitochondrial
substrates for bioenergetics (Criscuolo et al. 2006), but it is
uncertain whether these actions would occur in a terminally
differentiated neuronal cell which has very limited ability
to utilize biofuels other than glucose. Knockdown of
UCP2, if it functions simply as an uncoupling protein,
should limit the ability of protons to bypass Complex V
(ATP synthase). Thus, protons re-entering the mitochon-
drial matrix would be expected to be more likely to stim-
ulate ATP production. In fact, knockdown of UCP2
decreased ATP synthesis, consistent with a previous report
(Diano et al. 2003), which showed that overexpression of
UCP2 led to increased ATP synthesis. In our study, the
combination of leptin and MPP
? treatment in UCP2
knockdown cells led to a greater reduction in ATP levels
than seen in these cells exposed to MPP
? only. The reasons
for this observation are unclear. Nevertheless, we postulate
that this further decrease in intracellular ATP level con-
tributes to the abolition of leptin protection in UCP2
knockdown cells.
The observed leptin protection via increased UCP2
expression is not the only protective action of leptin. Effects
outside mitochondria have been reported by other groups
(Esler et al. 1998; Scarpace et al. 2000; Ceddia et al. 2000).
Leptin is known to activate AMPK, which is known to
increases b-oxidation and thus modulate cellular ATP/ADP
ratio (Bla ´zquez et al. 1999). Nevertheless, glucose is by far
the major provider of neuronal energy needs (Edmond et al.
1987), whereas other energy substrates, such as fatty acids,
represent only up to 20% of brain oxidative energy produc-
tion (Ebert et al. 2003). It is unlikely that the attenuation of
MPP
?-induced ATP deﬁciency by leptin in our neuronal
340 Neurotox Res (2010) 17:332–343
123culture was solely due to stimulation of b-oxidation by lep-
tin-activated AMPK activity (Bla ´zquez et al. 1999). Instead,
we observed a signiﬁcant preservation of MMP by leptin in
ourcontrolcells,whichcontributedtotheattenuationofATP
deﬁciency induced by MPP
?. This protective effect against
mitochondrial depolarization by leptin was completed
abolished after UCP2-knockdown. UCP2 has been shownto
play a criticalrole in maintainingmitochondrial functionsin
neurons (Arsenijevic et al. 2000; Andrews et al. 2006).
Although we observed a higher MMP after UCP2-knock-
down, these cells have signiﬁcantly lower ATP levels, even
under normal culture conditions. The reasons for this
observationareunclear.However,itisclearthatsuppressing
UCP2 expression failed to maintain normal mitochondrial
functioning. Similar observations were observed in immor-
talized embryonic ﬁbroblasts from UCP2 knockout mice
which exhibited a signiﬁcant decrease in ATP/ADP ratio as
compared with cells from wild-type littermates (Pecqueur
et al. 2008). Our current ﬁndings support UCP2 as a critical
candidate in regulating ATP levels by leptin.
Another factor which might involve in the protective
leptin pathway is the increase of UCP4 expression in this
MPP
? toxicity model. UCP4 is a neuronal speciﬁc UCP
homologuewhichsharesabout33%aminoacididentitywith
UCP2 (Mao et al. 1999). Functional studies of UCP4 have
been described (Chu et al. 2009; Chan et al. 2006; Liu et al.
2006; Zhang et al. 2006; Yu et al. 2000). In this study,
knockdown of UCP2 in neuronal culture signiﬁcantly
increased UCP4 expression; however, this inductive effect
was not observed in another neuronal UCP homologue,
UCP5 (Kim-Han et al. 2001; Ho et al. 2006). This supports
the concept of differentiation in functions among these UCP
homologues as we suggested previously (Ho et al. 2005).
We recently reported that UCP4 overexpression pro-
tected neuronal cells against MPP
? toxicity by preserving
ATP levels and suppressing oxidative stress (Chu et al.
2009). Classical mitochondrial uncoupling was suggested
to depolarize MMP and decrease ATP levels (Andrews
et al. 2005; Brookes, 2005), but UCP4 overexpression
signiﬁcantly increased ATP production by promoting res-
piration rate (Chu et al. 2009). In this study, MPP
? depo-
larized the inner mitochondrial membrane and reduced
ATP levels in vector control cells, whereas in UCP2-
knockdown cells, MPP
? had no effect on ATP levels,
possibly because of a compensatory increase of UCP4 level
after knocking down UCP2, thus maintaining ATP levels
similar to its respective untreated control. We hypothesize
that this ﬁnding is a reﬂection of the differing interactions
between UCP2 and UCP4, in preserving mitochondrial
homeostasis, and might partly contribute to the protective
effects observed in this current model. Such synergistic
interaction between UCP2 and UCP4 has been previously
reported (Yasuno et al. 2007).
In conclusion, leptin is protective against MPP
?-
induced mitochondrial depolarization and ATP deﬁciency
in neuronal cells. Our ﬁndings showed a crucial link
between UCP2 expression and the neuroprotective effects
of leptin against MPP
? toxicity. The absence of these
protective effects by leptin after knockdown of UCP2 is the
ﬁrst evidence to demonstrate a critical role of mitochon-
drial UCP2 in mediating such effects of leptin in neuronal
cells to preserve energy supply. It is possible that the res-
toration of ATP levels was attributed to a potential facili-
tation of oxidative phosphorylation as shown by
preservation of MMP by the presence of UCP2, and a
compensatory increase of UCP4, which likely help to
preserve ATP levels in MPP
? toxicity. It might be possible
to develop therapeutic strategies using leptin or its struc-
tural analogs to increase mitochondrial efﬁciency to pre-
vent or delay neuronal degeneration as a consequence of
mitochondrial dysfunction.
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